{"id":394144,"date":"2020-12-07T08:03:09","date_gmt":"2020-12-07T13:03:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=394144"},"modified":"2020-12-07T08:03:09","modified_gmt":"2020-12-07T13:03:09","slug":"enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/","title":{"rendered":"Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy"},"content":{"rendered":"<div class=\"mw_release\">\n<p>Nes Ziona, Israel, Dec.  07, 2020  (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a new patent to the Company, carrying a patent number\u00a0ZL201380071109.8. The patent covers Allocetra<sup>TM<\/sup>, the Company\u2019s immunotherapy product candidate.\u00a0 The new patent provides added intellectual property protection in China, including methods, uses and pharmaceutical compositions.<\/p>\n<p>Allocetra<sup>TM<\/sup> has been designed to\u00a0provide a novel immunotherapy mechanism of action\u00a0that targets life-threatening clinical indications that are defined as \u201cunmet medical needs\u201d, including\u00a0organ dysfunction and acute multiple organ failure associated with Sepsis and COVID-19, as well as treating solid tumors by modulating the tumors\u2019 microenvironment.<\/p>\n<p>\n        <strong>ABOUT ENLIVEX<\/strong>\n      <\/p>\n<p>Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs) such as sepsis and COVID-19, as well as enhancement of immune activity against solid tumors in combination with CAR-T or immune checkpoint therapies. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4g-hEHeDpRgD21SZEPHbMuMLKglzFmX1LPY_RbmxhPpvy0EMSzsa8sDbLY-THSB1iWivLxX2LxhAOrsk2aGd4hoi60S7WbTr_RupsquQAqQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>http:\/\/www.enlivex.com.<\/u><\/a><\/p>\n<p>\n        <em>Safe Harbor Statement:\u00a0 This press release contains forward-looking statements, which may be identified by words such as \u201cexpects,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cshould,\u201d \u201cwould\u201d, \u201ccould,\u201d \u201cintends,\u201d \u201cestimates,\u201d \u201csuggests,\u201d \u201chas the potential to\u201d and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA<sup>TM<\/sup>\u00a0programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.\u00a0 Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex\u2019s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and\/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA<sup>TM<\/sup>\u00a0product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.\u00a0 In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex\u2019s filings with the Securities and Exchange Commission, including in the Company\u2019s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.\u00a0 The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.<\/em>\n      <\/p>\n<p>\n        <strong>ENLIVEX CONTACT<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/> Shachar Shlosberger, CFO\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/> Enlivex Therapeutics, Ltd.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HFXBdTtIf-PSfY1axU3r5mgzPbudY5HpAwmUb6G6qfR6PeHRRn_VvvvNQYEMOTX3Wr_tYqLjmcCGMGVoiuHMEnEb6Z2T5vfxjFhTpIaJ7uM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>shachar@enlivexpharm.com<\/u><\/a><\/p>\n<p>\n        <strong>INVESTOR RELATIONS CONTACT<\/strong><br \/>\n        <br \/>Eric Ribner<br \/>LifeSci Advisors<br \/>eric@lifesciadvisors.com<\/p>\n<p>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  <\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzU0MyMzODU4NzY0IzUwMDA2NTE3NA==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/37245770-1a26-4873-9f14-743158b1b63b\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nes Ziona, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a new patent to the Company, carrying a patent number\u00a0ZL201380071109.8. The patent covers AllocetraTM, the Company\u2019s immunotherapy product candidate.\u00a0 The new patent provides added intellectual property protection in China, including methods, uses and pharmaceutical compositions. AllocetraTM has been designed to\u00a0provide a novel immunotherapy mechanism of action\u00a0that targets life-threatening clinical indications that are defined as \u201cunmet medical needs\u201d, including\u00a0organ dysfunction and acute multiple organ failure associated with Sepsis and COVID-19, as well as treating solid tumors by modulating the tumors\u2019 microenvironment. ABOUT ENLIVEX Enlivex is a clinical stage immunotherapy company, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-394144","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Nes Ziona, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a new patent to the Company, carrying a patent number\u00a0ZL201380071109.8. The patent covers AllocetraTM, the Company\u2019s immunotherapy product candidate.\u00a0 The new patent provides added intellectual property protection in China, including methods, uses and pharmaceutical compositions. AllocetraTM has been designed to\u00a0provide a novel immunotherapy mechanism of action\u00a0that targets life-threatening clinical indications that are defined as \u201cunmet medical needs\u201d, including\u00a0organ dysfunction and acute multiple organ failure associated with Sepsis and COVID-19, as well as treating solid tumors by modulating the tumors\u2019 microenvironment. ABOUT ENLIVEX Enlivex is a clinical stage immunotherapy company, &hellip; Continue reading &quot;Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-07T13:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzU0MyMzODU4NzY0IzUwMDA2NTE3NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy\",\"datePublished\":\"2020-12-07T13:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\\\/\"},\"wordCount\":607,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NzU0MyMzODU4NzY0IzUwMDA2NTE3NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\\\/\",\"name\":\"Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NzU0MyMzODU4NzY0IzUwMDA2NTE3NA==\",\"datePublished\":\"2020-12-07T13:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NzU0MyMzODU4NzY0IzUwMDA2NTE3NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NzU0MyMzODU4NzY0IzUwMDA2NTE3NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/","og_locale":"en_US","og_type":"article","og_title":"Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy - Market Newsdesk","og_description":"Nes Ziona, Israel, Dec. 07, 2020 (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a new patent to the Company, carrying a patent number\u00a0ZL201380071109.8. The patent covers AllocetraTM, the Company\u2019s immunotherapy product candidate.\u00a0 The new patent provides added intellectual property protection in China, including methods, uses and pharmaceutical compositions. AllocetraTM has been designed to\u00a0provide a novel immunotherapy mechanism of action\u00a0that targets life-threatening clinical indications that are defined as \u201cunmet medical needs\u201d, including\u00a0organ dysfunction and acute multiple organ failure associated with Sepsis and COVID-19, as well as treating solid tumors by modulating the tumors\u2019 microenvironment. ABOUT ENLIVEX Enlivex is a clinical stage immunotherapy company, &hellip; Continue reading \"Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-07T13:03:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzU0MyMzODU4NzY0IzUwMDA2NTE3NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy","datePublished":"2020-12-07T13:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/"},"wordCount":607,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzU0MyMzODU4NzY0IzUwMDA2NTE3NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/","name":"Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzU0MyMzODU4NzY0IzUwMDA2NTE3NA==","datePublished":"2020-12-07T13:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzU0MyMzODU4NzY0IzUwMDA2NTE3NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzU0MyMzODU4NzY0IzUwMDA2NTE3NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-announces-issuance-of-new-chinese-patent-covering-allocetra-immunotherapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=394144"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394144\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=394144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=394144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=394144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}